# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price tar...
Truist Securities analyst Srikripa Devarakonda maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and maintains $25 pr...
Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $26 price target.
"We are pleased by the promising and consistent functional results observed over two years of treatment with sevasemten, to...
RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $28 price...
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight rating and ...
– Company to host an Industry Forum to discuss its approach to protecting and preserving dystrophic muscle featuring key opinio...